Solowij Nadia, Broyd Samantha J, Beale Camilla, Prick Julie-Anne, Greenwood Lisa-Marie, van Hell Hendrika, Suo Chao, Galettis Peter, Pai Nagesh, Fu Shanlin, Croft Rodney J, Martin Jennifer H, Yücel Murat
School of Psychology and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia.
The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), New Lambton Heights, Australia.
Cannabis Cannabinoid Res. 2018 Mar 1;3(1):21-34. doi: 10.1089/can.2017.0043. eCollection 2018.
Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While Δ-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to ameliorate cognitive, symptomatic, and brain harms in cannabis users. However, this has never been tested in a prolonged administration trial in otherwise healthy cannabis users. Here, we report the first study of prolonged CBD administration to a community sample of regular cannabis users in a pragmatic trial investigating potential restorative effects of CBD on psychological symptoms and cognition. Twenty frequent cannabis users (16 male, median age 25 years) underwent a 10-week open-label trial of 200 mg of daily oral CBD treatment, while continuing to use cannabis as usual. The majority of participants were daily cannabis users who had used cannabis for several years (median 5.5 years of regular use). Participants underwent psychological and cognitive assessments at baseline (BL) and post-treatment (PT) and were monitored weekly throughout the trial. CBD was well tolerated with no reported side effects; however, participants retrospectively reported reduced euphoria when smoking cannabis. No impairments to cognition were found, nor were there deleterious effects on psychological function. Importantly, participants reported significantly fewer depressive and psychotic-like symptoms at PT relative to BL, and exhibited improvements in attentional switching, verbal learning, and memory. Increased plasma CBD concentrations were associated with improvements in attentional control and beneficial changes in psychological symptoms. Greater benefits were observed in dependent than in nondependent cannabis users. Prolonged CBD treatment appears to have promising therapeutic effects for improving psychological symptoms and cognition in regular cannabis users. Our findings require replication given the lack of a placebo control in this pragmatic trial, but suggest that CBD may be a useful adjunct treatment for cannabis dependence.
长期使用大麻与认知功能受损和心理症状加剧有关,尤其是类似精神病的体验。虽然Δ-四氢大麻酚(THC)被认为是这些有害影响的主要原因,但大麻二酚(CBD)据称具有抗精神病特性,并能改善大麻使用者的认知、症状和脑损伤。然而,这从未在健康大麻使用者的长期给药试验中得到验证。在此,我们报告了第一项针对普通大麻使用者社区样本进行的CBD长期给药研究,该研究是一项务实试验,旨在调查CBD对心理症状和认知的潜在恢复作用。20名经常使用大麻的人(16名男性,中位年龄25岁)接受了为期10周的开放标签试验,每天口服200毫克CBD治疗,同时继续照常使用大麻。大多数参与者是每天使用大麻数年的人(中位常规使用时间为5.5年)。参与者在基线(BL)和治疗后(PT)接受了心理和认知评估,并在整个试验过程中每周进行监测。CBD耐受性良好,未报告副作用;然而,参与者回顾性报告称,吸食大麻时欣快感降低。未发现认知受损,对心理功能也没有有害影响。重要的是,与BL相比,参与者在PT时报告的抑郁和类似精神病的症状明显减少,并且在注意力转换、言语学习和记忆方面有所改善。血浆CBD浓度升高与注意力控制改善和心理症状的有益变化相关。与非依赖大麻使用者相比,依赖大麻使用者的获益更大。长期CBD治疗似乎对改善普通大麻使用者的心理症状和认知具有有前景的治疗效果。鉴于这项务实试验缺乏安慰剂对照,我们的研究结果需要重复验证,但表明CBD可能是治疗大麻依赖的一种有用辅助治疗方法。